Investing.com -- Morgan Stanley cut its rating on Novo Nordisk to Underweight from Equal-weight and lowered its price target ...

Firm Novo Nordisk’s global patent is set to expire in parts of the world from early 2026, allowing cut-price ‘own-label’ ...

The job cuts represent around 11% of the Ozempic and Wegovy maker’s 78,400 global staff, with the company aiming to deliver total annual savings of around 8 billion Danish kroner, equivalent to $1.25 ...

Novo Nordisk A/S rose the most in a month after its diabetes blockbuster Ozempic beat Eli Lilly & Co.’s older drug Trulicity ...

Pocketpills operates four fulfilment centres across Canada to deliver medications in all provinces except Quebec ...

Novo Nordisk's Q2 2025 sales surge as Wegovy demand grows, driven by new obesity drug data. Click here to read an analysis of ...

Soon, there may be a promising alternative for the needle-averse, as results of a recent Phase 3 trial confirmed that a daily ...

Ozempic, marketed by Novo Nordisk in India, is primarily indicated for the treatment of type 2 diabetes. While it can lead to ...

Novo Nordisk's Ozempic launch adds to its GLP-1 portfolio, offering patients new options while competing with Eli Lilly's ...

When compared to dulaglutide, Ozempic was associated with a reduced risk of major adverse cardiovascular events such as a heart attack or stroke by 23%. The results of the REACH study were recently ...

Because of its size, the drugmaker has an outsize effect on the country. Now, as it sheds jobs, forecasts for Denmark’s ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.